The Journal of Immunology, Vol 157, Issue 10 4390-4398, Copyright © 1996 by American Association of Immunologists

ARTICLES

Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation

NV Sherbina, PS Linsley, S Myrdal, LS Grosmaire, JA Ledbetter and GL Schieven
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.

CD22 is a key accessory molecule for Ag receptor signaling in B cells that becomes tyrosine phosphorylated in the signaling process. CD22 associates with sIg and strongly amplifies sIg-induced signals. During B cell development, CD22 is initially expressed intracellularly, with surface expression appearing with IgD expression. We used confocal laser-scanning microscopy and flow cytometry to analyze CD22 translocation responses to signaling events. Cross-linking surface IgM (sIgM) induced rapid movement of CD22 to the cell surface in both Ramos and Daudi B cells, with a 50 to 100% increase in surface expression observed within 5 min of stimulation. The increase in CD22 surface expression was specific in that CD19 expression was not affected. Both cell surface and intracellular CD22 were directed toward the site of sIgM stimulation. Treatment with the phosphotyrosine phosphatase inhibitor bis(maltolato)oxovanadium(IV) also increased CD22 surface expression. The tyrosine kinase inhibitor tyrphostin A10 inhibited CD22 movement at concentrations that inhibited tyrosine phosphorylation of CD22 and other cellular proteins. In contrast to the B cell lines, mature peripheral blood B cells contained very little intracellular CD22 and showed no significant increase in surface expression following sIgM stimulation. The rapid directed movement of intracellular CD22 provides a new mechanism to dynamically regulate Ag receptor signaling, as well as CD22-mediated adhesion.

This article has been cited by other articles:

				J. Carnahan, P. Wang, R. Kendall, C. Chen, S. Hu, T. Boone, T. Juan, J. Talvenheimo, S. Montestruque, J. Sun, et al. Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22: Characterization of in Vitro Properties Clin. Cancer Res., September 1, 2003; 9(10): 3982S - 3990. [Abstract] [Full Text] [PDF]

				B. John, B. R. Herrin, C. Raman, Y.-n. Wang, K. R. Bobbitt, B. A. Brody, and L. B. Justement The B Cell Coreceptor CD22 Associates with AP50, a Clathrin-Coated Pit Adapter Protein, Via Tyrosine-Dependent Interaction J. Immunol., April 1, 2003; 170(7): 3534 - 3543. [Abstract] [Full Text] [PDF]

				Y. Abe, C. W. Smith, J. P. Katkin, L. M. Thurmon, X. Xu, L. H. Mendoza, and C. M. Ballantyne Endothelial {alpha}2,6-Linked Sialic Acid Inhibits VCAM-1- Dependent Adhesion Under Flow Conditions J. Immunol., September 1, 1999; 163(5): 2867 - 2876. [Abstract] [Full Text] [PDF]

				C. H. T. Chan, J. Wang, R. R. French, and M. J. Glennie Internalization of the Lymphocytic Surface Protein CD22 Is Controlled by a Novel Membrane Proximal Cytoplasmic Motif J. Biol. Chem., October 23, 1998; 273(43): 27809 - 27815. [Abstract] [Full Text] [PDF]

				L. Jin, P. A. McLean, B. G. Neel, and H. H. Wortis Sialic Acid Binding Domains of CD22 Are Required For Negative Regulation of B Cell Receptor Signaling J. Exp. Med., May 6, 2002; 195(9): 1199 - 1205. [Abstract] [Full Text] [PDF]